Having trouble accessing articles? Reset your cache.

July 1 P&P Quick Takes: FDA guidance on heart failure endpoints; plus upcoming CBER guidances and more

FDA issues draft guidance to spur development of heart failure drugs
FDA issued a draft guidance describing the agency's thinking on clinical endpoints for heart failure drugs that could re-ignite cardiovascular drug development. The guidance noted that effect on symptoms or physical function

Read the full 420 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers